US Pen Needles Market worth $ 1.53 billion by 2031
The report "US Pen Needles Market by Type (Standard Pen Needles, Safety Pen Needles), Length (8mm, 5mm), Setting (Home Care Settings), Application (Glucagon-like Peptide-1 Therapy), Mode of Purchase (Over-the-counter Purchase, Online Purchase)- Forecast to 2031" is projected to grow from USD 0.93 billion in 2026 and to reach USD 1.53 billion by 2031, at a Compound Annual Growth Rate (CAGR) of 10.4% during the forecast period.
Browse 150 market data Tables and 50 Figures spread through 200 Pages and in-depth TOC on "US Pen Needles Market by Type (Standard Pen Needles, Safety Pen Needles), Length (8mm, 5mm), Setting (Home Care Settings), Application (Glucagon-like Peptide-1 Therapy), Mode of Purchase (Over-the-counter Purchase, Online Purchase)- Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/us-pen-needles-market-9759386.html
Growing populations dependent on insulin in the US fuel pen needle markets are driven by the growing prevalence of diabetes, aging, and inactivity, and mass movements to the more convenient and accurate dosing techniques of insulin-pen delivery, which are then further built on for increased proven high rates of replacement frequency and increased patient unit demand. Innovations in products are steady, ranging from fine-gauge short lengths, low-tear tips, and safety-engineered designs, which are gaining adoption, alongside digital/telehealth channels that enable e-pharmacy and fulfillment through subscriptions. Reduced pace of growth includes steep price competition and commoditization from payer/reimbursement variability, favoring standard lower-cost needles, as well as possible erosion of demand as patients adopt more non-insulin therapies (GLP-1s/weight loss drugs) and pay policy initiatives lowering insulin prices, for any of these pressures could result in less volume or tighter margins for insulin. It is a tough challenge, but there are significant opportunities: premiumization on the safety and ultra-low-trauma lines, the launch of smart/connected disposables, deeper direct-to-patient and mail-order models, OEM supply agreements with pen manufacturers, value-based contracting, and patient-education programs to capture higher-margin shares and counteract commoditization.
This report categorizes the pen needles market based on type, length, application, mode of purchase, setting, and region.
“The standard pen needles segment accounted for the largest share of the US pen needles market in 2024.”
The standard pen needles segment accounts for the largest share of the U.S. pen needles market, due to their broad compatibility with almost any insulin pen, thereby making them the first choice across all retail pharmacies, hospitals, and mail-order channels. Standard needles align with the reimbursement policies and formulary preferences of payers, who are often inclined toward low-cost, high-volume consumables. These needles are familiar to patients and clinicians alike, requiring minimal training, which facilitates more consistent adherence. Standard needles are manufactured in bulk by major suppliers, which guarantee their availability and price stability, thereby further endorsing procurement preference. Together, all these factors create sustained, high-volume demand that puts standard pen needles in the strongest position of dominance for the US market.
“The online purchase segment is expected to grow at the highest CAGR during the forecast period of the US pen needles market.”
The segment of online purchases is expected to show the largest CAGR in the US pen needles market, owing to the rising adoption of e-pharmacies, subscription refill modes, and direct-to-patient delivery services, which meet the high-frequency replacement requirements of insulin users. Increased levels of comfort with digital health platforms, the extension of telemedicine prescribing, and the broader acceptance of mail-order pharmacies by insurance packages are driving shifts from retail stores to online fulfillment. The strategy implementation by large players such as Amazon, Walmart, and major pharmacy chains toward same-day and auto-refill services reduces the consumer’s burden and increases price visibility for their products. In conjunction with individual home management of diabetes, these online channels are poised for sustained above-market growth during the forecast period.
Key Market Players:
Key players in this market are adopting several organic and inorganic growth strategies (such as product launches, agreements, collaborations, acquisitions, and expansions). Prominent players in this market include Embecta Corp. (US), Novo Nordisk A/S (Denmark), MTD Medical Technology and Devices (Italy), B. Braun SE (Germany), Owen Mumford (UK), Terumo Corporation (Japan), NIPRO Corporation (Japan), Allison Medical, Inc. (US), AdvaCare Pharma (US), Berpu Medical Technology Co., Ltd. (China), ARKRAY, Inc. (Japan), GlucoRx Limited (UK), HTL-STREFA (Poland), UltiMed, Inc. (US), Artsana Group (Italy), PromiseMed Medical Devices Inc. (Canada), Montmed, Inc. (Canada), Trividia Health, Inc. (US), VOGT Medical Vertrieb GmbH (Germany), Van Heek Medical (Netherlands), Simple Diagnostics (US), IYON Medical (Turkey), Links Medical Products, Inc. (US), and MHC Medical Products, LLC (US).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the US Pen Needles Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
